PubMed · 6870169
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
C Combescure. 1983. [A technic for breast augmentation].. https://pubmed.ncbi.nlm.nih.gov/6870169/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Fibroblasts and myofibroblasts from normal, fibrotic or tumoral breast tissues present multiple quantitative differences in gene expression even when grown in isolation. We were therefore prompted to investigate whether one could recognize various subtypes by their constitutive-gene expression profile. Quantitative autoradiographic data for 34 constitutively expressed transcripts were submitted to multivariate analysis of variance, followed by discriminant analysis and single linkage cluster analysis. Models assuming up to 8 putative fibroblast subtypes (among fibroblasts or myofibroblasts from breast skin, normal mammary stroma, tumor-adjacent "normal" stroma, post-radiation fibrosis lesions and benign or malignant tumors) and an epithelial-cell group used as an internal control resulted in 100% correct classification. Myofibroblasts from various origins clustered close to, although distinctly apart from, their corresponding alpha-smooth-muscle-actin-negative counterparts. Malignant tumor fibroblasts were phenotypically more distant from normal cells compared with other pathological types. Our results support the hypothesis of co-adaptive transformation of stromal and epithelial tissues during breast tumoral development and suggest that different types of fibroblasts give rise to different types of myofibroblasts. Discriminant analysis of quantitative molecular variation may be considered for the development of a powerful artificial-intelligence method for cell typing and should be particularly useful when no reliable discrete molecular markers are available.
Interferon gamma (IFNgamma) induces growth arrest in normal human mammary epithelial cells by establishing a block during mid-G1 corresponding to the time when the retinoblastoma protein (Rb) would normally be inactivated by hyperphosphorylation. IFNgamma inhibits the kinase activities of cdk2, cdk4 and cdk6 within 24 h of treatment. Protein levels of the cdks and G1 cyclins do not change within this time period, although cdk4 levels are significantly reduced by 48 h. IFNgamma treatment induces p27Kip1 protein levels, presumably by a post-transcriptional mechanism as no change was observed in the mRNA levels. In addition, IFNgamma-induced inhibition of cdk2 and cyclin E-associated kinase activities is accompanied by a 4.5-fold or greater increase of p27Kip1 in cdk2 complexes. p27 may also have a role in the inhibition of cdk4/6 kinase activities, as p27 protein associated with these complexes was increase by 55-70% after IFNgamma. In mammary carcinoma cell lines which are resistant to growth inhibition by IFNgamma, p27 levels are not induced by IFNgamma nor is cdk2 kinase activity inhibited, despite high baseline levels of p27 in cdk2 complexes. However, exogenous expression of p27 in these cells induces growth arrest. In addition, purified p27 protein added to cdk2 complexes immunoprecipitated from carcinoma cells is able to inhibit the kinase activity in a dose dependent manner. Our results suggest that p27Kip1 has a role in mediating IFNgamma-induced terminal growth arrest. Resistance of mammary carcinomas to growth inhibition by IFNgamma does not appear to involve resistance of cdk2 complexes to the action of p27, but rather an inability to appropriately regulate the balance of cdk2, cyclin E and p27 levels.
Explore the source record for details and available documents.